Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.

Autor: Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zugmaier G; Amgen Research (Munich), GmbH, Munich, Germany., Agrawal V; Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, California, USA., Martínez-Sánchez P; Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain., Rifón Roca JJ; Hematology and Hemotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain., Cassaday RD; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Böll B; First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany., Rijneveld A; Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands., Abdul-Hay M; Perlmutter Cancer Center, New York University Langone Health, New York, New York, USA., Huguet F; Department of Hematology, Institut Universitaire du Cancer-Oncopole CHU de Toulouse, Toulouse, France., Cluzeau T; Université Nice Côte d'Azur, CHU de Nice, Nice, France., Díaz MT; Hematology Department, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain., Vucinic V; Department of Hematology and Cell Therapy, University Hospital Leipzig, Leipzig, Germany., González-Campos J; Hematology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Rambaldi A; Department of Oncology-Hematology, University of Milan, Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Schwartz S; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany., Berthon C; Centre Hospitalier Universitaire de Lille, Lille, France., Hernández-Rivas JM; IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, Salamanca, Spain.; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.; CIBERONC, Research Group CB16/12/00233, Salamanca, Spain., Gordon PR; Amgen Inc., Thousand Oaks, California, USA., Brüggemann M; Department of Hematology, University of Schleswig-Holstein, Kiel, Germany., Hamidi A; Amgen Inc., Thousand Oaks, California, USA., Chen Y; Amgen Inc., Thousand Oaks, California, USA., Wong HL; Clinical Pharmacology, Modeling and Simulation, Amgen Inc., South San Francisco, California, USA., Panwar B; Amgen Inc., Thousand Oaks, California, USA., Katlinskaya Y; Amgen Inc., Thousand Oaks, California, USA., Markovic A; Amgen Inc., Thousand Oaks, California, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Apr; Vol. 99 (4), pp. 586-595. Date of Electronic Publication: 2024 Feb 05.

Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study.

Autor: de Beijer IAE; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. i.a.e.debeijer-3@prinsesmaximacentrum.nl., Hardijzer EC; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Haupt R; IRCCS Istituto Giannina Gaslini, Genoa, Italy., Grabow D; Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center, of the Johannes Gutenberg University Mainz, Mainz, Germany., Balaguer J; Hospital Universitario y Politécnico La Fe, Valencia, Spain., Bardi E; St. Anna Children's Hospital, Vienna, Austria.; Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria., Cañete Nieto A; Hospital Universitario y Politécnico La Fe, Valencia, Spain., Ciesiūniene A; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania., Düster V; St. Anna Children's Hospital and Children's Cancer Research Institute, Department of Studies and Statistics for Integrated Research and Projects, Department of Paediatrics, Medical University of Vienna, Vienna, Austria., Filbert AL; Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center, of the Johannes Gutenberg University Mainz, Mainz, Germany., Gsell H; CCI Europe, Vienna, Austria., Kapitančukė M; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania., Ladenstein R; St. Anna Children's Hospital and Children's Cancer Research Institute, Department of Studies and Statistics for Integrated Research and Projects, Department of Paediatrics, Medical University of Vienna, Vienna, Austria., Langer T; Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lübeck, Germany., Muraca M; IRCCS Istituto Giannina Gaslini, Genoa, Italy., van den Oever SR; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Prikken S; University Hospitals Leuven, KU Leuven, Louvain, Belgium., Rascon J; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania., Tormo MT; Instituto de Investigación Sanitaria La Fe, Valencia, Spain., Uyttebroeck A; University Hospitals Leuven, KU Leuven, Louvain, Belgium., Vercruysse G; University Hospitals Leuven, KU Leuven, Louvain, Belgium., van der Pal HJH; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Kremer LCM; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, the Netherlands.; Department of Pediatrics, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Pluijm SMF; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.

Publikováno v: Journal of cancer survivorship : research and practice [J Cancer Surviv] 2023 Nov 28. Date of Electronic Publication: 2023 Nov 28.